# Extended thrombotic prophylaxis in COVID-19 early discharge: A retrospective cohort study

**Authors:** Sebastiaan T. van’t Hoff, Gea Helfrich, Sanne Boerman, Hans A. Hardeman

PMC · DOI: 10.1371/journal.pone.0340889 · PLOS One · 2026-01-30

## TL;DR

This study found no difference in blood clots or readmissions between patients given a blood thinner and those who weren't after being discharged for COVID-19.

## Contribution

The study provides new evidence that extended thrombotic prophylaxis may not be necessary for early-discharged COVID-19 patients.

## Key findings

- No significant difference in VTE occurrence between groups with and without nadroparin prophylaxis.
- No difference in readmissions, including those due to VTE, between the two groups.
- The study suggests thrombotic prophylaxis may not be necessary for home monitoring of COVID-19 patients.

## Abstract

Due to limits in available staff and space during the COVID-19 pandemic, home monitoring programmes were introduced, reducing strain on resources, and preventing readmissions. Several hospitals included prophylaxis for venous thrombotic events (VTE), as COVID-19 appeared to be thrombogenic. Other hospitals did not, expecting patients to be more mobile while at home. Our aim was to determine whether the administration of nadroparin has led to a difference in VTE occurrence between two groups of previously included patients.

Retrospective cohort study of two cohorts included in home monitoring with the same protocol, except for nadroparin prophylaxis.

663 patients were analysed in equal groups from two hospitals. No significant difference was found in occurrence of VTE after discharge, readmissions in general or readmissions due to VTE in otherwise comparable groups.

As opposed to trials determining thrombotic prophylaxis was of benefit after discharge due to COVID-19, we found no difference between our groups. Our study was retrospective and comprised data compiled over almost two years, which provides a relatively large sample size and overview through different treatment regimes.

For the future, thrombotic prophylaxis for COVID-19 home monitoring might not be indicated and reconsidered for different home monitoring programmes.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** thrombotic (MESH:D013927), venous thrombotic (MESH:D020246), COVID-19 (MESH:D000086382)
- **Chemicals:** nadroparin (MESH:D017762)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12857994/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12857994/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12857994/full.md

---
Source: https://tomesphere.com/paper/PMC12857994